Advanced Malignant Solid Tumors Clinical Trial
Official title:
Clinical Study on the Treatment of Advanced Malignant Solid Tumors With the Combination of mRNA
Verified date | June 2023 |
Source | Stemirna Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab injection (hereinafter referred to as Sintilimab) in the treatment of advanced malignant solid tumors.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | March 20, 2026 |
Est. primary completion date | December 12, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Are =18 years old, without limitation of sex at time of consent. - Patients with malignant solid tumors confirmed by histopathology or cytology and having at least one measurable lesion. - Fresh biopsy specimens can be provided for vaccine preparation. - Patients with malignant solid tumors who develop secondary drug resistance after receiving PD-1/PD-L1 drug therapy, including but not limited to gastric cancer, esophageal cancer, and other gastrointestinal tumors of MSI-H Exclusion Criteria: - It is known that it is allergic to any tumor vaccine and Sintilimab preparations; Or have experienced severe allergic reactions to other monoclonal antibodies in the past; - The predicted number of new antigens is less than 10; - Those who are pregnant or breastfeeding; - Those with an expected survival period of less than 3 months; |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Stemirna Therapeutics | Peking University Cancer Hospital & Institute |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression-free survival (PFS) | Time Frame: from enrolling to patients disease progression,assessed up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00728468 -
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
|
Phase 1 | |
Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00768469 -
Study Evaluating Safety And Tolerability, Solid Tumor
|
Phase 1 | |
Recruiting |
NCT04226066 -
Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04908046 -
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06464055 -
A Study of GQ1010 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06231550 -
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05383703 -
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
|
Phase 1 | |
Recruiting |
NCT05773937 -
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT04328506 -
Bioequivalency Study of CM082 Tablet in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05886374 -
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT00958724 -
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT02045095 -
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00884845 -
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05277454 -
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
|
Phase 1 | |
Active, not recruiting |
NCT03792958 -
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT00997360 -
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT04126668 -
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05338957 -
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
|
Phase 1/Phase 2 | |
Recruiting |
NCT03047811 -
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
|
N/A |